Completed PHASE3 INTERVENTIONAL 2-arm NCT00976456

Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer (65plus)

Open-label Study of Bevacizumab (Avastin®) in Combination With Pemetrexed or Pemetrexed and Carboplatin as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer

Sponsor: Eli Lilly and Company

Conditions Non-squamous Non-small Cell Lung Cancer

Interventions Bevacizumab + Pemetrexed Bevacizumab + Pemetrexed + Carboplatin

Updated 5 times since 2017 Last updated: Feb 11, 2016 Started: Sep 30, 2009 Primary completion: Oct 31, 2014 Completion: Oct 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Non-squamous Non-small Cell Lung Cancer, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 5 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
PD Dr. med. Wolfgang Schuette
Roche Pharma AG

Data source: Martha-Maria Krankenhaus Halle-Dölau gGmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Halle, Germany